D. R. Korst, M.D. (Assoc.); E. P. Frenkel, M.D. (Assoc.)
This content is PDF only. Please click on the PDF icon to access.
Three rather important developments in the study and treatment of plasmocytic myeloma have occurred in the past three years. These are an experimental animal tumor with all the characteristics of the human myeloma; refined techniques to study abnormal myeloma proteins of serum and urine by filter paper, starch gel, and immunoelectrophoresis; and the clinical trial of a new alkylating agent, cyclophosphamide (Cytoxan) in human cases.
A mouse myeloma tumor produces a plasmocytic tumor, bone marrow and spleen involvement, and a typical myeloma electrophoretic pattern at 60 days after inoculation. Resection of the mass of tumor causes a decrease (day 64)
Korst DR, Frenkel EP. Recent Developments in Multiple Myeloma.. Ann Intern Med. 1962;56:694. doi: 10.7326/0003-4819-56-4-694_1
Download citation file:
© 2019
Published: Ann Intern Med. 1962;56(4):694.
DOI: 10.7326/0003-4819-56-4-694_1
Hematology/Oncology, Multiple Myeloma.
Results provided by: